Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study
Table 1
Baseline characteristics of the population.
Patients with SVT ( = 90)
Age (years), median (IQR)
50 (39–62)
Males, (%)
47/90 (52.2%)
Personal history of VTE, (%)
7/90 (7.8%)
Family history of VTE, (%)
8/90 (8.9%)
Asymptomatic incidentally detected SVT, (%)
11/90 (12.2%)
Risk factor
Unprovoked SVT, (%)
33/90 (36.7%)
Liver cirrhosis, (%)
14/90 (15.6%)
Solid cancer, (%)
6/90 (6.7%)
Myeloproliferative neoplasm, (%)
7/90 (7.8%)
Recent abdominal surgery, (%)
10/90 (11.1%)
Hormonal therapy, female (%)
11/43 (25.6%)
Inflammatory bowel disease, (%)
5/90 (5.6%)
Other intra-abdominal inflammation or infection, (%)
7/90 (7.8%)
Involved veins
Multiple veins thrombosis, (%)
33/90 (36.7%
Isolated portal vein thrombosis, (%)
35/90 (38.9%)
Isolated mesenteric veins thrombosis, (%)
16/90 (17.8%)
Isolated suprahepatic vein thrombosis, (%)
1/90 (1.1%)
Isolated splenic vein thrombosis, (%)
5/90 (5.6%)
Genetic mutations
JAK2 V617F mutation, tested (%)
3/42 (7.1%)
Prothrombin G20210A mutation, tested (%)
4/55 (7.3%)
Factor V Leiden mutation, tested (%)
5/58 (8.6%)
Previous anticoagulant treatment
VKA treatment duration (months), median (IQR)
12.4 (7.1–23.8)
Less than 3 months, (%)
7/90 (7.8%)
3–6 months, (%)
10/90 (11.1%)
6–12 months, (%)
22/90 (24.4%)
1 year or more, (%)
51/90 (56.7%)
Time within therapeutic range (%), median (IQR)
62 (56–75.5)
Multiple risk factors are possible. Of these 33 patients, 20 had two veins involved (16 portomesenteric venous thrombosis) and 13 had three veins involved (all portosplenomesenteric venous thrombosis). IQR = interquartile range, SVT = splanchnic vein thrombosis, VKA = vitamin K antagonist, and VTE = venous thromboembolism.
